Mirum Pharmaceuticals Management
Management criteria checks 2/4
Mirum Pharmaceuticals' CEO is Chris Peetz, appointed in Mar 2019, has a tenure of 5.17 years. total yearly compensation is $6.45M, comprised of 10.2% salary and 89.8% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth €7.21M. The average tenure of the management team and the board of directors is 2.3 years and 3.8 years respectively.
Key information
Chris Peetz
Chief executive officer
US$6.5m
Total compensation
| CEO salary percentage | 10.2% |
| CEO tenure | 5.2yrs |
| CEO ownership | 0.6% |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$660k | -US$163m |
| Sep 30 2023 | n/a | n/a | -US$164m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$129m |
| Dec 31 2022 | US$4m | US$624k | -US$136m |
| Sep 30 2022 | n/a | n/a | -US$42m |
| Jun 30 2022 | n/a | n/a | -US$53m |
| Mar 31 2022 | n/a | n/a | -US$70m |
| Dec 31 2021 | US$4m | US$600k | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$179m |
| Jun 30 2021 | n/a | n/a | -US$153m |
| Mar 31 2021 | n/a | n/a | -US$132m |
| Dec 31 2020 | US$3m | US$512k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$84m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$6m | US$458k | -US$53m |
| Sep 30 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$385k | US$32k | -US$26m |
Compensation vs Market: Chris's total compensation ($USD6.45M) is above average for companies of similar size in the German market ($USD1.63M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Peetz (44 yo)
5.2yrs
Tenure
US$6,451,720
Compensation
Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He also serves as Entrepreneur-in-Residence at Frazier Life Sciences Managem...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.2yrs | US$6.45m | 0.64% $ 7.2m | |
| COO & President | 4.1yrs | US$2.37m | 0.042% $ 480.2k | |
| Chief Financial Officer | less than a year | US$4.69m | 0.030% $ 335.9k | |
| Chief Scientific Officer | less than a year | US$1.51m | 0.20% $ 2.3m | |
| Vice President of Investor Relations and Finance | no data | no data | no data | |
| Chief Compliance Officer | 4.1yrs | no data | no data | |
| Senior Vice President of Human Resources | 5.3yrs | no data | no data | |
| Consultant | less than a year | US$1.98m | 0.033% $ 367.7k | |
| Chief Development Officer | 5.4yrs | US$1.51m | 0.20% $ 2.3m | |
| Senior vice President of Quality | 2.3yrs | no data | no data | |
| Senior Vice President of Technical Operations | 1.3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
2.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: 08D's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$6.45m | 0.64% $ 7.2m | |
| Independent Director | 5.5yrs | US$401.75k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$426.75k | 0.021% $ 239.9k | |
| Independent Non-Executive Chairman of the Board | 5.2yrs | US$451.75k | 0.81% $ 9.2m | |
| Independent Director | 4.9yrs | US$421.75k | 0.014% $ 162.0k | |
| Independent Director | 1.1yrs | US$671.53k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$411.75k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$194.47k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$411.75k | 0% $ 0 |
3.8yrs
Average Tenure
57yo
Average Age
Experienced Board: 08D's board of directors are considered experienced (3.8 years average tenure).